Economic Survey 2025-26: Pharma industry shifting from volume to value driven approach, the report tabled in Parliament on Thursday, highlights India’s evolving pharmaceutical sector. Economic Survey 2025-26: Pharma industry shifting from volume to value driven approach reflects a move from mass production of generics to high-value, innovation-led products.

The Survey notes that beyond generics, India is a global leader in supplying low-cost vaccines. The country produces the majority of the world’s DPT, BCG, and measles vaccines, contributing significantly to global immunization efforts.

Officials said the shift toward value-driven growth includes research and development of specialty medicines, biologics, and complex formulations. This transition aims to boost profitability and global competitiveness while maintaining affordability.

The Survey emphasized that supporting innovation, improving regulatory frameworks, and strengthening public-private partnerships are key to sustaining growth. Analysts said this strategy could position India as a hub for advanced pharmaceutical research and exports.

Industry experts highlighted that focusing on value rather than sheer volume will also help address emerging global health challenges and improve access to advanced therapies worldwide.

The Survey concluded that a balanced approach—maintaining India’s dominance in generics while moving into high-value segments—is essential for long-term growth.